We have located links that may give you full text access.
JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
Functionalized Fullerene Targeting Human Voltage-Gated Sodium Channel, hNa v 1.7.
ACS Chemical Neuroscience 2017 August 17
Mutations of hNav 1.7 that cause its activities to be enhanced contribute to severe neuropathic pain. Only a small number of hNav 1.7 specific inhibitors have been identified, most of which interact with the voltage-sensing domain of the voltage-activated sodium ion channel. In our previous computational study, we demonstrated that a [Lys6 ]-C84 fullerene binds tightly (affinity of 46 nM) to Nav Ab, the voltage-gated sodium channel from the bacterium Arcobacter butzleri. Here, we extend this work and, using molecular dynamics simulations, demonstrate that the same [Lys6 ]-C84 fullerene binds strongly (2.7 nM) to the pore of a modeled human sodium ion channel hNav 1.7. In contrast, the fullerene binds only weakly to a mutated model of hNav 1.7 (I1399D) (14.5 mM) and a model of the skeletal muscle hNav 1.4 (3.7 mM). Comparison of one representative sequence from each of the nine human sodium channel isoforms shows that only hNav 1.7 possesses residues that are critical for binding the fullerene derivative and blocking the channel pore.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app